hope there are some new messages!!...we need something new here! but my guess is we'll have to wait to closer to end of year. It would be nice if we had somebody who could dissect the Xalkori announcement. My understanding is that while it is a cmet inhibitor, the approval solely relates to its ability to inhibit ALK. Certainly is the case that treatments for NSCLC are going to focus on small subsets of patients and will bring significant benefit.